Abstract
The thiazolidinediones were introduced as oral hypoglycemic drugs in Sweden during the fall of 2000. A case is reported in which a woman with insulin-dependent type-2 diabetes and both macro- and microangiopathy and pronounced insulin resistance was treated with rosiglitazone (Avandia). Within three months insulin doses could be reduced by 36% (from 176 to 112 units insulin daily) and concomitantly Ery-HbA1c was reduced from 8.4 to 5.3%. In spite of this dramatic effect on glucose homeostasis administration of the drug had to be discontinued due to critical congestive heart failure.
| Translated title of the contribution | A case report. Rosiglitazone treatment was highly effective yet had to be terminated |
|---|---|
| Original language | Swedish |
| Pages (from-to) | 407-410 |
| Journal | Läkartidningen |
| Volume | 99 |
| Issue number | 5 |
| Publication status | Published - 2002 |
Subject classification (UKÄ)
- Endocrinology and Diabetes
- Nutrition and Dietetics
